Bisphosphonate matrix metalloproteinase inhibitors for the treatment of periodontitis: An in vitro study

MARIANNA DE COLLI1, PAOLO TORTORELLA2, MARIANGELA AGAMENNONE1, CRISTINA CAMPESTRE3, FULVIO LOIODICE2, AMELIA CATALDI1 and SUSI ZARA1

1Department of Pharmacy, University ‘G. d’Annunzio’ Chieti-Pescara, I-66100 Chieti; 2Department of Pharmacy-Pharmaceutical Science, University ‘A. Moro’ Bari, I-70125 Bari, Italy

Received October 16, 2017; Accepted March 15, 2018

DOI: 10.3892/ijmm.2018.3641

Abstract. Periodontitis is an inflammatory disease caused by anaerobic bacteria, including Porphyromonas gingivalis. Lipopolysaccharide (LPS)-stimulated persistent inflammation is responsible for an increase in matrix metalloproteinase (MMP) expression, resulting in periodontal tissue destruction. The aim of the present study was to investigate synthesized bisphosphonic MMP inhibitors, in an in vitro model consisting of human gingival fibroblasts exposed to LPS, and to compare the biological responses to those induced by zoledronate (ZA), a commercial bisphosphonate. MTT and lactate dehydrogenase (LDH) assays were used to measure cell viability and cytotoxicity, respectively. ELISA was performed to evaluate prostaglandin E2 (PGE2) interleukin (IL)6 and collagen secretion, while western blotting was used to analyze MMP expression. No effect on viability and low cytotoxicity were observed following treatment with bisphosphonate compounds. In the present study, treatment with compound 1 did not increase the release of PGE2 and IL6. Increased levels of collagen I secretion were reported when compound 3 and ZA were administered. An increase of MMP8 was observed following ZA treatment, while a decrease of MMP9 and MMP14 following treatment with compounds 1, 2 and ZA were reported. The performance of compound 1 was optimal in terms of cell viability. Compound 1 also did not induce inflammation, and had the ability to counteract LPS-induced increases in MMP expression. These data suggested that compound 1 was the most suitable treatment to progress to an in vivo animal study, with the aim to confirm its use for the treatment of periodontitis.

Introduction

Periodontitis is a chronic and frequent inflammatory disease that occurs due to an immune-inflammatory response to pathogenic subgingival microflora or to bacterial products, and is often responsible for loss of teeth in adults. In the presence of pathogenic oral bacteria, an altered host response is observed, leading to an augmented release of pro-inflammatory cytokines that results in chronic inflammation and progressive damage to soft and hard tooth-supportive structures (1). The majority of periodontal infections are provoked by Gram-negative, anaerobic bacteria, including Porphyromonas gingivalis, which serves a pivotal function in periodontal pathogenesis (2,3). P. gingivalis releases large amounts of lipopolysaccharide (LPS), which constantly stimulates host cells and modulates the immune-mediated inflammatory response. The interaction between LPS and toll-like receptors (4) is known to lead to the activation of different pathways responsible for the production of pro-inflammatory cytokines, including interleukin (IL)-1β and tumor necrosis factor (TNF)-α. The latter controls tissue remodeling under pathological conditions (5,6). LPS structure is heterogeneous among different bacterial species, thus stimulating different immune responses in host cells (6,7).

Matrix metalloproteinases (MMPs) are a large family of structurally-associated proteases, either expressed on the cell surface or secreted in extracellular space. They are characterized by a zinc-binding catalytic domain able to degrade several extracellular substrates (8,9). MMPs, being able to degrade the majority of extracellular matrix and basement membrane components, are often classified according to their specific substrates as collagensases or gelatinases (9).

MMPs serve a pivotal function in the balance between the deposition and the degradation of the extracellular matrix in periodontal tissue in physiological and pathological conditions. In gingival crevicular fluid or in peri-implant sulcular fluid, it is thought to be an indicator of periodontal tissue health condition (9,10).

Increased secretion of MMPs has been reported in chronic inflammatory conditions, including periodontitis, and leads to irreversible soft tissue destruction (11,12). MMPs are synthesized in periodontal tissue when exposed to pathogenic bacteria, including P. gingivalis (3). Several studies have already suggested that the LPS is able to increase MMP
expression in various types of cell, including human gingival fibroblasts (HGFs) (13).

As excessive production of MMPs is associated with several pathological processes, including cancer metastasis and chronic inflammatory conditions (12,14), over the last 20 years the synthesis of a variety of low-molecular weight MMP inhibitors has occurred, even though the majority are not commercially available (15). MMP inhibitor structure is characterized by a peptidomimetic fragment, usually placed in the prime region of the active site, and a zinc-binding group (ZBG) able to coordinate the zinc ion. Hydroxamate is considered to be the most effective ZBG. However, hydroxamate inhibitors lack high specificity due to the presence of the hydroxamic group, which has scarce pharmacokinetic properties and is of toxicological consequence (16).

An attempt was made to overcome this issue by synthesizing novel inhibitors that do not contain the zinc binding group (17) or containing an alternative, more selective functional group coordinating the zinc ion (18-20). Novel bisphosphonic (BP) MMP inhibitors have been synthesized (21,22) and their structural features include a BP group as the ZBG and an arylsulfonamide function that allows the correct positioning of the aryl portion in the MMP hydrophobic binding pocket. These compounds have been demonstrated to inhibit MMPs at nanomolar concentrations (21), and a number have been tested in vitro to analyse their activity on gingival fibroblasts, in comparison with zolendronate (ZA) (23). Furthermore, in a previous study, the effect of certain BPs on P. gingivalis growth and cytokine release by oral epithelial cells was evaluated (24).

Therefore, our group sought to test these compounds on human gingival fibroblasts (HGFs), exposed to LPS, in order to evaluate the biological response in terms of cell viability, cytotoxicity, inflammatory events and soft tissue destruction, in comparison with ZA, a commercially available bisphosphonic drug.

Materials and methods

Chemistry. Compounds 1, 2, 3 and zoledronic acid (Fig. 1) were synthesized as previously described in Rubino et al (21). The chemical characterization of studied compounds was as follows.

1-Hydroxy-2-(imidazol-1-yl)-ethylidene-1,1-bisphosphonic acid (ZA). Melting point (Mp): 220-3°C; 1H NMR [(D6)DMSO]: δ=4.49-4.56 (m, 2H, NCH2C), 7.21 (s, 1H, aromatic), 7.36, (s, 1H, aromatic), 8.56, (s, 1H, aromatic); 31P NMR [(D6)DMSO]: δ=14.83 (br, 2P, PCP). Mass spectrometry (MS) [electrospray ionization (ESI)] m/z: 271 [M-H]-; MS2 m/z (%): 243 (100); Anal. calcd for (C13H11N2O10P2) C 35.95%, H 4.18%, N 3.16%.

(4-Chloro-biphenyl-4-sulfonylamino)methyl-1,1-bisphosphonic acid (compound 1). Mp: 252°C (dec); 1H NMR [(D6)DMSO]: δ=3.78 (td, JHH=9.6, JHP=21.7, 1H, PCHP); 8.03-8.06, 8.28-8.30 (m, 2H, 2H, aromatic), 8.32-8.53 (br, 4H, OH and 1H, NH); 31P NMR [(D6)DMSO]: δ=14.59 (d, JPH=21.3, 2P, PCHP); MS (ESI) m/z: 375 [M-H]-; MS2 m/z (%): 357 [(M-H-H2O)-, 100]; Anal. calcd for (C13H11N2O10P2S2H2O): C 21.33%, H 3.07%, N 7.11%, found: C 21.05%, H 3.30%, N 6.76%.

Cytotoxicity assays. HGF membrane integrity was assessed by measuring lactate dehydrogenase (LDH) leakage into the medium, using a CytoTox 96 non-radioactive cytotoxicity assay (Promega Corporation, Madison, WI, USA), following the manufacturer's protocol, after 72 h of culture under the different experimental conditions. Cytotoxicity was evaluated using the following formula: % LDH released = [(A-B)-(C-B) x 100, as reported by De Colli et al (23).

ELISA analysis of prostaglandin E2 (PGE2), IL6 and collagen type I secretion. PGE2, IL6 and collagen type I secretion in the culture medium at different experimental times was detected using ELISA kits, following the manufacturer's protocols. The amount of PGE2, IL6 and collagen type I was assessed using enzyme immunoassay kits for PGE2 and IL6 (Enzo Life Sciences, Inc., Farmingdale, NY, USA; cat. no. ADL-900-001
and ADI-900-033, respectively) and a human collagen type I ELISA kit (Cosmo Bio Co., Ltd., Tokyo, Japan; cat. no. ACE-EC1-E105-EX). The absorption values were obtained using a spectrophotometer (Multiskan GO; Thermo Fisher Scientific, Inc., Waltham, MA USA) at the following wavelengths: 405 nm for PGE$_2$ and 450 nm for IL6 and collagen type I. PGE$_2$, IL6 and collagen type I secretion levels were measured in different wells and normalized for relative optical density (OD) values, as determined by the MTT assay, and expressed as pg/ml/OD MTT for PGE$_2$ and IL6, and as µg/ml/OD MTT for collagen type I (23).

Protein extraction and western blot analysis. HGFs were trypsinized and then centrifuged at 250 x g for 10 min at 4˚C to obtain pellets. Lysis buffer (0.5 ml) containing protein inhibitors cocktail (PBS, 1% IgePal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml PMSF, 1 mg/ml aprotinin, 100 mM sodium orthovanadate and 50 µg/ml leupeptin) was added to the cell pellets and set on ice for 30 min. The lysed pellets were then re-suspended and kept on ice for a further 30 min. Following centrifugation for 15 min at 20,000 x g at 4˚C, supernatants were collected as whole cell fractions. Protein concentration was determined using a Bicinchoninic Acid assay (QuantiPro™ BCA Assay kit for 0.5‑30 µg/ml protein, cat. no. QPBCA-1KT; Sigma-Aldrich Merck KGaA, Darmstadt, Germany) according to the manufacturer's protocols. Total protein electrophoresis, nitrocellulose membrane transfer and blocking were performed as previously reported by De Colli et al (23). Briefly, total protein content (30 µg) was electrophoresed via a 4‑20% SDS‑PAGE and transferred to nitrocellulose membranes. Following blocking with 5% non‑fat milk, 10 mM Tris‑HCl pH 7.5 and 100 mM NaCl, 0.1% Tween‑20 at room temperature for 1 h, the nitrocellulose membranes were then probed overnight at 4˚C with rabbit polyclonal anti‑MMP‑8 (cat. nos. sc‑8782 and sc‑50383, respectively; 1:200; Sigma Aldrich; Merck KGaA), anti‑MMP9 and anti‑MMP14 (cat. no. IM37; 1:1,000; Calbiochem; Merck KGaA; cat. no. orb166952; 1:200; Biorbyt Ltd., Cambridge, UK, respectively) primary antibodies, and mouse anti β‑actin primary antibodies (cat no. A5616; 1:5,000; Sigma‑Aldrich; Merck KGaA). Membranes were then washed in PBS and 0.1% Tween-20 three times for 10 min for each, and then probed for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit immunoglobulin G (cat. nos. 401253 and 401393, respectively; 1:20,000, Calbiochem; Merck KGaA), as previously described (23). Immunoreactive bands were detected using an enhanced chemiluminescence detection system (GE Healthcare Life Sciences, Little Chalfont, UK) and analyzed by densitometry. Densitometric values, expressed as integrated optical intensity, were estimated in a CHEMIDOC XRS system with QuantiOne 1-D analysis software (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Values obtained were normalized based on densitometric values of internal β-actin.

Statistical analysis. Statistical analysis was performed using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA), and data were evaluated using one-way analysis of variance followed by the Student-Newman-Keuls post hoc test. The results were expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference (25).

Results

Metabolic activity decreases when compounds 2, 3 and ZA are administered. The MTT assay revealed that all the compounds causes a statistically significant decrease of metabolic activity when compared with the LPS-treated sample. This reduction was particularly apparent in the LPS+ZA-treated sample, with respect to the samples treated with LPS and other compounds. Furthermore, treatment with compounds 2 and 3 significantly reduced HGF metabolic activity compared with the LPS+1‑treated sample (Fig. 2).

Compounds 1, 2 and 3, in contrast to ZA, preserve membrane integrity. To measure compound-induced cytotoxicity, the LDH assay was performed, revealing that LPS treatment induced relatively high LDH leakage. Treatment with compounds 1, 2 and 3 reduced LDH release compared with the LPS-treated group, while treatment with ZA increased LDH release compared with the LPS-treated group (Fig. 3).

Compound 1 does not contribute to inflammation. The secretion level of pro-inflammatory cytokine IL6 and the eicosanoid mediator PGE$_2$ was assessed using ELISA assays,
and a similar trend for these molecules was identified. The PGE$_2$ secretion level is similar in the LPS+1-treated sample and the LPS-treated, while an increased level was recorded in the LPS+2, 3 and the ZA-treated samples, compared with the LPS-treated sample. In addition, there was a statistically significant increase in PGE$_2$ secretion levels in the ZA-treated HGFs compared with all other experimental conditions; but PGE$_2$ secretion decreased in HGFs treated with LPS+1 compared with LPS+2 and 3-treated samples (Fig. 4A). With regards to the IL6 secretion level, there was a significant increase in LPS+ZA-treated samples compared with other experimental groups, and a significant increase in IL6 secretion was also detected in the LPS+3-treated sample compared with the LPS+1-treated cells (Fig. 4B).

**Treatment with compound 3 and ZA induces an increase of collagen I secretion in the cell culture medium.** As collagen I represents the most abundant protein secreted by the HGFs, collagen I secretion was measured to evaluate cell adhesion and functionality. The ELISA assay revealed a statistically significant increase of protein secretion in the LPS+3 and ZA-treated samples compared with the LPS-treated samples, and a significant increase was identified in the LPS+ZA-treated samples compared with the LPS+1, 2, and 3-treated samples. A significant increase of collagen I secretion was observed in the LPS+3 and ZA-treated samples compared with the LPS+1-treated cells (Fig. 5).

**Effects of treatment with ZA and compounds 1, 2 and 3 on MMPs.** The expression of MMPs, the most important proteases involved in connective tissue remodeling, were also analyzed using western blotting. The inhibitory ability
of novel synthesized BPs were analyzed using MPP-8, ‑9 and ‑14 (21). MMP8 expression was significantly augmented in the LPS+1, 2, 3 or ZA (100 µM) for 72 h. (A) The most representative gel images from three separate experiments are presented. (B) The histogram represents densitometric values as the mean ± standard deviation, expressed as IOI. *P<0.05 vs. LPS+ZA. MMP, matrix metalloproteinase; LPS, lipopolysaccharide; ZA, zoledronate; IOI, integrated optical intensity.

Discussion

Periodontitis is a common disease characterized by chronic microbial infection, which leads to chronic inflammation and damage to connective tissue and alveolar bone (26). Although >600 bacterial species have been identified in the oral cavity, previous studies have indicated that periodontitis is induced by the accumulation of Gram-negative bacteria in the dental biofilm, including P. gingivalis (27). The major periodontal pathogen P. gingivalis, and/or the LPS it releases, are known to be potent stimulators of inflammation (3). In parallel to inflammatory events, which are characterized by leukocyte activation and involvement, and also by the release of pro-inflammatory cytokines, an increase in MMP synthesis also contributes to periodontal tissue breakdown (8). At present, the mechanical removal of pathogenic bacteria and the administration of tetracyclines, traditionally considered inhibitors of MMPs (28), are considered effective interventions for the treatment of periodontitis.

Excessive production of MMPs is frequently associated with several pathological processes, including cancer metastasis and chronic inflammatory conditions (12,14). Over the last 20 years, the synthesis of a variety of low-molecular weight MMP inhibitors has been promoted, even if the majority of these are not commercially available due to a lack of selectivity, pharmacokinetics and toxicological problems (29). An attempt was made to overcome this issue by synthesizing novel inhibitors with an improved selectivity profile. From a structural point of view, they are comprised of a BP group connected to the aryl portion through a sulfonamide linker. The bisphosphonate function was inspired by other clinically used compounds, including zoledronate; the aryl portion inserts in the specificity pocket of the enzymes that contribute to MMP selective inhibition, while the sulfonamide linker serves a crucial function in directing the aryl portion into the MMP hydrophobic selectivity pocket correctly. These

Figure 6. Western blot analysis of MMP8 expression in human gingival fibroblasts treated with LPS or LPS+compound 1, 2, 3 or ZA (100 µM) for 72 h. (A) The most representative gel images from three separate experiments are presented. (B) The histogram represents densitometric values as the mean ± standard deviation, expressed as IOI. *P<0.05 vs. LPS+ZA. MMP, matrix metalloproteinase; LPS, lipopolysaccharide; ZA, zoledronate; IOI, integrated optical intensity.

Figure 7. Western blot analysis of MMP9 and MMP14 expression in human gingival fibroblasts treated with LPS or LPS+compound 1, 2, 3 or ZA (100 µM) for 72 h. (A) The most representative gel images from three separate experiments are presented. The histograms represent densitometric values as the mean ± standard deviation, expressed as IOI, for (B) MMP9 and (C) MMP14, respectively. *P<0.05 vs. LPS, #P<0.05 vs. LPS+3. MMP, matrix metalloproteinase; LPS, lipopolysaccharide; ZA, zoledronate; IOI, integrated optical intensity.
molecules demonstrate MMP inhibitory activity at nanomolar concentrations (21,22).

According to MMP inhibition ability and preliminary survival assay results, as reported in Rubino et al (21), three BP MMP inhibitors were selected and tested in an in vitro model consisting of HGFs exposed to P. gingivalis LPS, the most important factor in the pathogenesis of periodontal disease. The cells were then treated for 72 h, while maintaining LPS exposure, with these BP compounds. The effects were compared with ZA, which is the most widely used BP drug with a chemical structure resembling that of the tested compounds.

As reported in previous studies, LPS stimulation is able to maintain high levels of cell viability (30,31). The addition of compound 1 was demonstrated to be able to preserve this beneficial effect, allowing the maintenance of a high rate of cell viability throughout the treatment.

With regards to the evaluation of cytotoxic potential, the results of the present study highlighted the difference in effect between the novel synthesized compounds and ZA: All three novel molecules were able to restore HGF membranes integrity, which is compromised following LPS treatment; but membrane integrity still appeared damaged when the HGFs were exposed to ZA. This evidence is not surprising, as our group had reported it in previous studies (23,32), and it was also reported in several other papers (33,34) which clearly underline the ZA toxicity on a fibroblast population.

LPS is regularly used as an inflammatory stimulus in in vitro models, and the aim of the present study was to evaluate whether novel synthesized drugs would further induce the release of pro-inflammatory mediator, since the Toll-like receptor (TLR)4 signaling, triggered by LPS, leads to the production of inflammatory cytokines (30). Notably, when compound 1 was administered, there was no significant increase in inflammatory agents triggered by LPS treatment.

TLR receptors, stimulated by endogenous and exogenous ligands, including LPS, serve a pivotal role by triggering signaling pathways that culminate in inflammatory gene induction, leading to the accumulation of large amounts of collagen and other ECM proteins in gingival tissues (35). The model used in the present study demonstrated that collagen secretion in all the experimental groups was aligned with the release of pro-inflammatory cytokines. The results caused our group to hypothesize that MMP8 activity contributes to high levels of collagen I secretion, when compound 3 or ZA are administered. MMP8 is known to modulate ECM and non-matrix molecules and, in particular, is known for its ability to effectively degrade collagen type I. Furthermore, MMP8 is produced by different types of cell, including gingival fibroblasts, during various inflammatory diseases which include periodontitis (36,37).

The involvement of MMPs in periodontal disease is well recognized as these proteins are synthesized in periodontal tissues in response to bacteria, including P. gingivalis, thus contributing to irreversible tissue destruction (11,12). It is for this reason that research was extended to other MMP isoforms in the present study. Based on the results of the present study, treatment with compounds 1 and 2 was able to counteract the increase of MMPs recorded during periodontal disease and, notably, this effect was perfectly observed for MMP9 and 14. This ability is also attributed to ZA, however this may not be considered a useful drug in our experimental model as all other measured biological parameters clearly underlined the induction of cytotoxicity, suggesting poor tolerability. In addition, compound 3 was inadequate as a treatment in the present model of periodontitis, as it failed to solve the imbalance of connective tissue remodeling, as demonstrated by MMP expression.

For diseases characterized by altered matrix turnover, including periodontitis, compounds with the capability to inhibit MMPs may be useful, as these may restore the balance between matrix apposition and matrix degradation. In the present study, which utilized an in vitro model of periodontitis, compound 1 demonstrated the most optimal performance as it was able to maintain a high level of cell viability without significantly inducing the inflammatory response, counteracting the increase in MMP expression. In conclusion, compound 1 appears to be the most suitable treatment, and should be included in an in vivo animal study in order to confirm its use as a treatment for periodontitis, and to evaluate the pharmacokinetic profile of the molecule.

Acknowledgements

Not applicable.

Funding

The present study was supported by a Cataldi FAR Grant (2015) and a Zara FAR Grant (2015).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MDC performed the biological experiments, PT and MA synthesized and provided the compounds, CC performed the statistical analysis, FL realized the preliminary chemical test, AC coordinated the research project and SZ designed the experimental project. All authors read and approved the manuscript.

Ethics approval and consent to participate

The present study was approved by the Local Ethical Committee of the University of Chieti (Chieti, Italy; approval no. 1173, approved on 31/03/2016). All donors provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.